Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Adverse effects of treatment · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo BMD Z score (total hip/femoral neck) · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | MD 0.15 [0.11, 0.19] | 1 study · 37 participants | Moderate |
Summary of findings – zinc vs placebo BMD Z score (lumbar spine) · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | MD 0.15 [0.1, 0.2] | 1 study · 37 participants | Moderate |
Summary of findings – zinc vs placebo BMD Z score (wrist) · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Incidence of fractures · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Mobility · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment BMD Z score (lumbar spine) · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Quality of life · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Adverse effects of treatment · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo BMD Z score (total hip/femoral neck) · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | MD 0.05 | 1 study · 63 participants | Low |
Summary of findings – denosumab vs placebo BMD Z score (lumbar spine) · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | 1 study · 63 participants | Low |
Summary of findings – denosumab vs placebo BMD Z score (wrist) · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | 1 study · 63 participants | Low |
Summary of findings – denosumab vs placebo Incidence of fractures · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Mobility · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Quality of life · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Adverse effects of treatment · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo BMD Z score (total hip/femoral neck) · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment BMD Z score (wrist) · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo BMD Z score (lumbar spine) · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | 1 study · 24 participants | Very low |
Summary of findings – strontium ranelate vs placebo BMD Z score (wrist) · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo Incidence of fractures · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo Mobility · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo Quality of life (back pain VAS score in cm) · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | 1 study · 24 participants | Very low |
Summary of findings – strontium ranelate vs placebo Adverse effects of treatment · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment Incidence of fractures · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | 1 study · 118 participants | Moderate |
Summary of findings – bisphosphonates vs placebo or no treatment Mobility · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment Quality of life (change in mean back pain) · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | 1 study · 118 participants | Very low |
Summary of findings – bisphosphonates vs placebo or no treatment Adverse effects of treatment · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | OR 15 | 2 studies · 143 participants | Very low |
Intervention NR BMD Z score (total hip/femoral neck) · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
Intervention NR BMD Z score (lumbar spine) · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | MD 0.43 [0.1, 0.76] | 1 study · 26 participants | Very low |
Summary of findings ‐ monotherapy: lumacaftor vs placebo Survival · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 2 studies · 147 participants | Low |
Summary of findings ‐ monotherapy: cavosonstat vs placebo Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 24 participants | Very low |
Summary of findings ‐ monotherapy: cavosonstat vs placebo FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: cavosonstat vs placebo FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
Summary of findings ‐ monotherapy: cavosonstat vs placebo Adverse events: occurring in at least 10% of cavosonstat‐treated participants · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
Summary of findings ‐ monotherapy: cavosonstat vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo Survival · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 2 studies · 1108 participants | High |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo Quality of life ‐ (EuroQol) EQ‐5D‐3L Index Score (total score): absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 2 studies · 1061 participants | Moderate |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo Quality of life ‐ CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 3 studies · 1139 participants | Moderate |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 3 studies · 1134 participants | High |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 3 studies · 1134 participants | Moderate |
Summary of findings ‐ monotherapy: lumacaftor vs placebo Quality of life ‐ total score · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo Adverse events · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 2 studies · 1108 participants | High |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 2 studies · 1108 participants | Moderate |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo Survival · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 204 participants | Moderate |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo Quality of life ‐ total score · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo Quality of life ‐ CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 204 participants | Low |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 204 participants | Low |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo Adverse events · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 204 participants | Low |